A Pilot Trial of the Use of ReCell® Autologous Cell Harvesting Device for Venous Leg Ulcers

AVITA Medical

Status and phase: Completed; Phase 4

Conditions: Venous Leg Ulcers

Treatments: Device: Standard Care plus ReCell; Other: Standard Care

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01743053

CTP003

Details and patient eligibility

About

This is a prospective, randomised, open label, controlled pilot study to evaluate the safety and preliminary effectiveness of the ReCell Autologous Cell Harvesting Device (ReCell) for the management of chronic leg ulcers associated with venous insufficiency. Outcome will be compared between study participants receiving standard care (debridement, compression therapy) and participants receiving ReCell in addition to standard care.

Enrollment: 52 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Chronic venous leg ulcer (CEAP Clinical classification of 6)

   1. Confirmed, actively managed venous reflux
   2. No exposed tendon or bone
   3. Ulcer is >4 weeks in duration
   4. Ulcer surface area between 2cm2 and 80cm2

2. ABI ≥ 0.8

3. The patient is 18 years of age or older

4. The patient is willing to complete all follow-up evaluations required by the study protocol

5. The patient is able to abstain from any other treatment of the ulcer for the duration of the study, unless medically necessary

6. The patient agrees to abstain from enrolment in any other clinical trial for the duration of the study

7. The patient is able to read and understand instructions and give voluntary written informed consent

8. The patient is able and willing to follow the protocol requirements (including compression therapy)

9. Patients enrolling at any site in France must have an affiliation to a social security scheme

Exclusion criteria

1. Study treatment area has exposed bone or tendon
2. Poorly controlled diabetes
3. Arterial insufficiency (ABI < 0.8)
4. Pregnant/lactating females (self-reported or tested, per institutional requirements)
5. The patient has an active wound infection requiring antibiotic therapy
6. The patient has had a prior surgical treatment of the ulcer within the past 60 days
7. The patient has a life expectancy of 1-year or less
8. The patient has a severe dermatological disorder (e.g. severe psoriasis, epidermolysis bullosa, pyoderma gangrenosum).
9. The patient is unable to follow the protocol
10. The patient is taking, or has taken in the past 60 days, mycophenolate mofetil or >10mg of corticosteroids per day.
11. The patient has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives
12. The patient has a known hypersensitivity to trypsin or Compound Sodium Lactate for Irrigation (Hartmann's) solution.
13. The patient is a vulnerable or protected adult.
14. The patient is unable to provide consent

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

52 participants in 2 patient groups

Control: Standard Care

Other group

Description:

The control group will receive standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa™ Clear).

Treatment:

Other: Standard Care

ReCell

Experimental group

Description:

The ReCell group will receive ReCell in addition to standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa Clear).

Treatment:

Device: Standard Care plus ReCell